"The Supreme Court on Monday refused to revive a challenge to Google’s digital library of millions of books, turning down an appeal from authors who said the project amounted to copyright infringement on a mass scale. The Supreme Court’s brief order left in place an appeals court decision that the project was a “fair use” of the authors’ work, ending a legal saga that had lasted more than a decade... As is their custom, the justices gave no reasons for declining to hear the case, Authors Guild v. Google Inc., No. 15-849. Last year, a unanimous three-judge panel of the United States Court of Appeals for the Second Circuit said that Google’s project was lawful and beneficial. “The purpose of the copying is highly transformative, the public display of text is limited and the revelations do not provide a significant market substitute for the protected aspects of the originals,” Judge Pierre N. Leval, an authority on copyright law, wrote for the panel."
Issues and developments related to IP, AI, and OM. My Bloomsbury book "Ethics, Information, and Technology" will be published in January 2026 and includes chapters on IP, AI, OM, and other emerging technologies (IoT, drones, robots, autonomous vehicles, VR/AR). Preorders are available via this webpage: https://www.bloomsbury.com/us/ethics-information-and-technology-9781440856662/
Monday, April 18, 2016
Challenge to Google Books Is Declined by Supreme Court; New York Times, 4/18/16
Adam Liptak, New York Times; Challenge to Google Books Is Declined by Supreme Court:
Obama’s Secrecy Problem; Slate, 4/15/16
Fred Kaplan, Slate; Obama’s Secrecy Problem:
"Steven Aftergood, director of the Project on Government Secrecy at the Federation of American Scientists, told me Thursday, “This is a time of particularly promising ferment over secrecy policy. There is a recognition, even within the national-security apparatus, that the classification system has overreached and needs to be pruned back.” Yet by all measures, the bureaucracies persist in resisting this pruning, Congress won’t allocate the money for the shears, and the president hasn’t mustered the full attention and commitment that the task requires. Information may want to be free, but Washington has it wrapped in a tangle."
Saturday, April 16, 2016
Artist Says Brazilian Protesters Copied His Giant Rubber Duck; New York Times, 4/1/16
Christopher Merle, New York Times; Artist Says Brazilian Protesters Copied His Giant Rubber Duck:
"The duck used in the demonstrations has X’s in place of its eyes and a Portuguese slogan across its chest that says: “We won’t pay for what is not our fault anymore.” But representatives for the Dutch artist, Florentijn Hofman, who is known for his outsize creations depicting animals, say they saw too many similarities between his rubber duck and the one used in Brazil — and they are not amused... A spokeswoman for Mr. Hofman, Kim Engbers, said in an email: “Of course we want to emphasize that it is a shame that this parody is used for propaganda. Our project is meant to be nonpolitical.” She added: “It is a positive work and has healing functions.” Ms. Engbers, however, stopped short of calling the Brazilians’ use of the rubber duck a copyright infringement."
Wednesday, April 13, 2016
Lifting the Patent Barrier to New Drugs and Energy Sources; New York Times, 4/12/16
Eduardo Porter, New York Times; Lifting the Patent Barrier to New Drugs and Energy Sources:
"Malaria has preyed on humans for centuries. Hundreds of thousands of children die each year from the disease. Considering the market’s size, why haven’t pharmaceutical companies rushed to develop a vaccine against the deadly parasite that causes it? The answer is easy: There is no money to be made from a vaccine for poor children who could not possibly pay for inoculation. Last year, GlaxoSmithKline finally introduced the world’s first malaria vaccine for large pilot tests among African children. The move, however, is not an endorsement of the profit motive as a spur for innovation. The Bill and Melinda Gates Foundation picked up much of the tab. And Glaxo does not expect to make money on its investment. The lack of interest of the pharmaceutical industry, which generates huge profits protected by a web of patents enforced around the world, raises an important question. Do we need a different way to spur innovation and disseminate new technologies quickly around the world? Are patents, which reward inventors by providing them with a government-guaranteed monopoly over their inventions for many years, the best way to encourage new inventions?"
‘We Shall Overcome’ Copyright May Be Overcome One Day; New York Times, 4/12/16
Ben Sisario, New York Times; ‘We Shall Overcome’ Copyright May Be Overcome One Day:
"Last year, a federal judge ruled that the long-claimed copyright to the song “Happy Birthday to You” was invalid. Now the same could happen for another iconic tune: “We Shall Overcome.” On Tuesday, the We Shall Overcome Foundation, a nonprofit group that works with orphans and the poor, sued the music publishers who control “We Shall Overcome,” seeking a declaratory judgment that the song is not under copyright and is in the public domain. The case, which was filed at Federal District Court in Manhattan and seeks class-action status, also asks for the return of an unspecified amount of licensing fees that the publishers, the Richmond Organization and Ludlow Music, have collected from the use of the song. Like the “Happy Birthday” case, the “We Shall Overcome” suit tracks a famous piece of music through a murky early history and a complex paper trail of copyright registrations."
Making the Most of Clinical Trial Data; New York Times, 4/12/16
Editorial Board, New York Times; Making the Most of Clinical Trial Data:
"Some researchers may oppose sharing data they have worked hard to gather, or worry that others will analyze it incorrectly. Creating opportunities for collaboration on subsequent analysis may help alleviate these concerns. Of course, any data sharing must take patients’ privacy into account; patients must be informed before joining a clinical trial that their data may be shared and researchers must ensure that the data cannot be used to identify individuals. By making data available and supporting analysis, foundations, research institutions and drug companies can increase the benefit of clinical trials and pave the way for new findings that could help patients."
Tuesday, April 12, 2016
Led Zeppelin members face trial in ‘Stairway to Heaven’ copyright infringement lawsuit; Washington Post, 4/12/16
Justin Wm. Moyer, Washington Post; Led Zeppelin members face trial in ‘Stairway to Heaven’ copyright infringement lawsuit:
"Led Zeppelin’s “Stairway to Heaven” has faced a lot of accusations in the 45 years since it was released. It’s overplayed, some say, particularly at high volumes by dudes trying to impress other dudes at guitar shops. It’s overlong, say others. And, for years, people have said “Stairway” sounds a lot like “Taurus” — a song by a much less famous band called Spirit who performed it allegedly while sharing bills with Zeppelin in the late 1960s. (You can listen for yourself here.) But after decades of gossip, members of Led Zeppelin — specifically, singer Robert Plant and guitarist Jimmy Page, the writers of “Stairway” — will face a jury trial on May 10. The question: Did they copy at least some parts of their most famous song?"
Subscribe to:
Posts (Atom)